会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明专利
    • Tricyclic quinoline and quinoxaline derivatives
    • NZ631187A
    • 2017-03-31
    • NZ63118713
    • 2013-09-13
    • ABBVIE INCABBVIE DEUTSCHLAND
    • DRESCHER KARLAHAUPT ANDREASKOOLMAN HANNESBRAJE WILFRIEDMACK HELMUTRELO ANA LUCIABAKKER MARGARETHA HENRICA MARIALAKICS VIKTORHOFT CAROLINXU RUXUZHAO XIAONA
    • C07D471/06A61K31/4353A61K31/4745A61K31/4985A61K31/551A61K31/5513C07D487/06
    • Disclosed are tricyclic quinoline and quinoxaline derivatives of formula (I) as vabicaserin analogues wherein, G is (CR3aR3b)n; X is NR6 or CR7R8; and wherein the remaining substituents are as defined herein. Representative compounds include 1,2,3,4-tetrahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1’-cyclopent[2]en]-6(7H)-one, 8-methyl-8-phenyl-3,4,7,8-tetrahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-6(2H)-one, 8,8-dimethyl-3,4,7,8-tetrahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-6(2H)-one, 12a-methyl-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline, (R)-5,6,7,9,9a,10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline, 9-chloro-8,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline, 1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1’-cyclohexane], 9-fluoro-1-methyl-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1’-cyclobutane], 2,3,5,6,7,8-Hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline, 1-Cyclobutyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline, 1-fluoro-5,6,7,9,9a,10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline, 8-Methyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-8-ol, 2,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-8-ol and 1-propyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound as defined above, or an N-oxide, a tautomeric form, a stereoisomer or a pharmaceutically acceptable salt thereof, or comprising at least one compound as defined above wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope, in combination with at least one pharmaceutically acceptable carrier and/or auxiliary substance, for the treatment of disorders which respond to the modulation of the 5-HT2c receptor, including disorders such as schizophrenia, depression, bipolar disorders, diabetes, obesity and substance use disorders.